Osteoclast Activation in Multiple Myeloma
作者： Sonia Vallet , Noopur Raje
DOI: 10.1007/978-1-60761-554-5_10
关键词: Osteoclast 、 Medicine 、 Osteoblast 、 Multiple myeloma 、 Cytokine 、 Cancer research 、 Bone marrow 、 Osteolysis 、 Bone disease 、 Bone remodeling
摘要: Osteolytic bone disease affects more than 80% of multiple myeloma (MM) patients with a negative impact on both quality life and overall survival. The pathogenesis osteolytic resides in increased osteoclast (OC) activation along osteoblast (OB) inhibition resulting altered remodeling. OC number activity MM are enhanced mainly via cytokine deregulation within the marrow (BM) milieu an imbalance OC/OB axis. Several novel agents currently under investigation for their positive effect remodeling or OB activation. In addition to restoring remodeling, these drugs may inhibit tumor growth vivo. Therefore, targeting is promising therapeutic strategy not only goal alleviating morbidity from but also resultant anti-tumor activity.
springer.com
sci-hub.st 参考文章(84)
D Chauhan, H Uchiyama, Y Akbarali, M Urashima, K Yamamoto, TA Libermann, KC Anderson, Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B Blood. ,vol. 87, pp. 1104- 1112 ,(1996) , 10.1182/BLOOD.V87.3.1104.BLOODJOURNAL8731104
Jason S. Damiano, Anne E. Cress, Lori A. Hazlehurst, Alexander A. Shtil, William S. Dalton, Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines Blood. ,vol. 93, pp. 1658- 1667 ,(1999) , 10.1182/BLOOD.V93.5.1658
Karin Vanderkerken, Evy De Leenheer, Claire Shipman, Kewal Asosingh, Angelo Willems, Ben Van Camp, Peter Croucher, None, Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Research. ,vol. 63, pp. 287- 289 ,(2003)
R Bataille, D Chappard, C Marcelli, P Dessauw, J Sany, P Baldet, C Alexandre, Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. Journal of Clinical Oncology. ,vol. 7, pp. 1909- 1914 ,(1989) , 10.1200/JCO.1989.7.12.1909
I von Metzler, H Krebbel, M Hecht, R A Manz, C Fleissner, M Mieth, M Kaiser, C Jakob, J Sterz, L Kleeberg, U Heider, O Sezer, Bortezomib inhibits human osteoclastogenesis. Leukemia. ,vol. 21, pp. 2025- 2034 ,(2007) , 10.1038/SJ.LEU.2404806
Aaron N. Nguyen, Elizabeth G. Stebbins, Margaret Henson, Gilbert O'Young, Sun J. Choi, Diana Quon, Debby Damm, Mamatha Reddy, Jing Y. Ma, Edwin Haghnazari, Ann M. Kapoun, Satyanarayana Medicherla, Andy Protter, George F. Schreiner, Noriyoshi Kurihara, Judy Anderson, G. David Roodman, Tony A. Navas, Linda S. Higgins, Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Experimental Cell Research. ,vol. 312, pp. 1909- 1923 ,(2006) , 10.1016/J.YEXCR.2006.02.026
R. S. Pearsall, E. Canalis, M. Cornwall-Brady, K. W. Underwood, B. Haigis, J. Ucran, R. Kumar, E. Pobre, A. Grinberg, E. D. Werner, V. Glatt, L. Stadmeyer, D. Smith, J. Seehra, M. L. Bouxsein, A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 7082- 7087 ,(2008) , 10.1073/PNAS.0711263105
Taina Taube, Monique N. C. Beneton, Eugene V. McCloskey, Susan Rogers, Mike Greaves, John A. Kanis, Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption European Journal of Haematology. ,vol. 49, pp. 192- 198 ,(2009) , 10.1111/J.1600-0609.1992.TB00046.X
Lori A. Ehrlich, Ho Yeon Chung, Irene Ghobrial, Sun Jin Choi, Francesca Morandi, Simona Colla, Vittorio Rizzoli, G. David Roodman, Nicola Giuliani, IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma Blood. ,vol. 106, pp. 1407- 1414 ,(2005) , 10.1182/BLOOD-2005-03-1080
Jean-Jacques Body, Philip Greipp, Robert E. Coleman, Thierry Facon, Filip Geurs, Jean-Paul Fermand, Jean-Luc Harousseau, Allan Lipton, Xavier Mariette, Catherine D. Williams, Arline Nakanishi, Donna Holloway, Steven W. Martin, Colin R. Dunstan, Pirow J. Bekker, A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases Cancer. ,vol. 97, pp. 887- 892 ,(2003) , 10.1002/CNCR.11138